Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

Five new commissioners appointed to medicines advisory body

Five new commissioners have been appointed to the Commission on Human Medicines (CHM), alongside several re-appointments.

  • Five new commissioners have been appointed to the Commission on Human Medicines (CHM).
  • The CHM provides independent expert advice to ministers on medicine safety, quality, and efficacy.
  • The appointments are for terms of either two or four years.

Five new commissioners have been appointed to the Commission on Human Medicines (CHM) for four-year terms, effective from 21 September 2026. The new appointees are Dr Andrew Hitchings, Dr Nigel Beckett, Dr Wajid Hussain, Professor Elvira Bramon, and Professor Sarah Danson.

The CHM is an advisory non-departmental public body, sponsored by the Department of Health and Social Care. Its role is to provide independent expert advice to ministers on the safety, quality, and efficacy of medicines, and to promote the collection and investigation of information related to adverse reactions to human medicines.

In addition to the new appointments, several commissioners have been re-appointed. Professor Anthony Williams, Professor David Dockrell, Professor David Hunt, Dr Geraldine Mortimore, and Julia Cons have been re-appointed for four years from 1 July 2026. Professor Paul Dargan and Professor Heather Wallace have been re-appointed for two years from 1 July 2026 and 1 September 2026, respectively. Professor David Moore has also been re-appointed for four years from 15 December 2026.

The roles involve an estimated time commitment of 22 days per year, including 11 meetings, with remuneration set at £325 per meeting. These appointments were made in accordance with the Cabinet Office Code of Governance for Public Appointments, with no political activity declared by any of the appointees.

Why this matters: The Commission on Human Medicines provides independent expert advice to ministers, influencing decisions on the safety, quality, and efficacy of medicines available to the public.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.